Sun Pharmaceutical Industries is trading higher by 3.5% at Rs 600, after falling nearly 7% in past four trading sessions on the Bombay Stock Exchange (BSE). The stock is largest gainer among benchmark index S&P BSE Sensex at 1020 hours.
Till yesterday, shares of drug maker has fallen 6.75% to Rs 580 from Rs 622 on March 5, on reports that the company has recalled 2,528 bottles of its generic version of diabetes drug Glumetza. The benchmark index has gained 2.6% during the same period.
According to FDA statement, Sun began recalling the bottles of metformin HCL extended-release tables on January 28, 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin.
The stock opened at Rs 583 and has seen a combined around 938,000 shares changed hands on the counter so far on the BSE and NSE.
Till yesterday, shares of drug maker has fallen 6.75% to Rs 580 from Rs 622 on March 5, on reports that the company has recalled 2,528 bottles of its generic version of diabetes drug Glumetza. The benchmark index has gained 2.6% during the same period.
According to FDA statement, Sun began recalling the bottles of metformin HCL extended-release tables on January 28, 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin.
The stock opened at Rs 583 and has seen a combined around 938,000 shares changed hands on the counter so far on the BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%